

24 **Author contributions:**

25 Conceptualization: CHG, CZ, PT, LG, LMM, KB, RB, FDB

26 Data curation, formal analysis, software, validation, visualization: CHG, CZ

27 Investigation, methodology: CHG, CZ, CH, LG, LMM

28 Resources: CHG, CZ, CH, PT, LG, LMM, FDB

29 Supervision, funding acquisition, project administration: RB, KB, FDB

30 Writing – Original draft preparation: CHG, FDB

31 Writing – Review & Editing: CHG, CZ, CH, PT, LG, RB, KB, LMM, FDB

32

33 **Corresponding authors information:**

34 **Frederic D. Bushman**

35 Department of Microbiology

36 3610 Hamilton Walk

37 426A Johnson Pavilion

38 Philadelphia, PA 19140-6076

39 bushman@penncmedicine.upenn.edu

40 (215) 573-8732

41 <https://orcid.org/0000-0003-4740-4056>

42

43 **Lisa Mattei**

44 Leonard and Madlyn Abramson Pediatric Research Center

45 3615 Civic Center Blvd, 9th floor

46 Philadelphia, PA 19104-6076

47 mattei@email.chop.edu

48 <https://orcid.org/0000-0002-2238-0281>

49

50 **Kyle Bittinger**

51 The Children's Hospital of Philadelphia

52 Microbiome Center

53 Roberts Center of Pediatric Research

54 2716 South Street, 14th floor

55 Philadelphia, PA 19146-2305

56 bittingerk@email.chop.edu

57 (267) 425-1641

58 <https://orcid.org/0000-0003-3472-5934>

60 **Abstract – 159**

61 *Mycobacterium chelonae* is a rapidly growing nontuberculous mycobacterium
62 that is a common cause of nosocomial infections. Here we describe investigation of a
63 possible nosocomial transmission of *M. chelonae* at the Hospital of the University of
64 Pennsylvania (HUP). *M. chelonae* strains with similar high-level antibiotic resistance
65 patterns were isolated from two patients who developed post-operative infections at HUP
66 in 2017, suggesting a possible point source infection. The isolates, along with other
67 clinical isolates from other patients, were sequenced using the Illumina and Oxford
68 Nanopore technologies. The resulting short and long reads were hybrid assembled into
69 draft genomes. The genomes were compared by quantifying single nucleotide variants in
70 the core genome and assessed using a control dataset for identity. We show that that all
71 *M. chelonae* isolates tested were highly divergent, consistent with environmental
72 acquisition. Additionally, antibiotic resistance genes were predicted for our isolates, and
73 several single nucleotide variants identified with the potential to modulated drug
74 susceptibility, providing candidate resistance mechanisms.

75

76 **Text – 3,699**

77 **Introduction**

78 *Mycobacterium chelonae*, a rapidly growing nontuberculous mycobacterium
79 (NTM), is ubiquitous in the environment and is a common source of infection in humans.
80 *M. chelonae* has caused several outbreaks from single point sources, but no human-to-
81 human transmission has been observed to date (1–6). *M. chelonae* is most commonly
82 associated with nosocomial soft tissue infections of the skin and eye, but can also cause
83 catheter-associated infections, disseminated and invasive infections, and pulmonary
84 infections (1). *Mycobacterium* can be highly resistant to many antibiotics because of their
85 naturally impermeable cell walls as well as mutation of bacterial genes that encode
86 antibiotic targets (7–9).

87 Among the *M. chelonae* isolates collected in 2017 from the Hospital of the
88 University of Pennsylvania (HUP) clinical microbiology laboratory were two isolates
89 from female patients who developed post-operative surgical site infections in breast
90 tissue. The patients underwent surgery within the same year, and yielded isolates showing
91 similar resistance patterns, raising the possibility of a nosocomial point source infection. To
92 investigate this possibility, we performed whole genome sequencing on every *M.*
93 *chelonae* isolate collected by the HUP clinical microbiology laboratory over a one-year
94 period (n=7) and examined differences in the single nucleotide variants (SNVs) of each
95 isolate's core genome. As a control, we created a dataset from a single *Vibrio campbellii*
96 strain that was sequenced 39 times independently, allowing us to determine a threshold of
97 SNVs that would distinguish different strains from sequencing error. Finally, we
98 investigated genes and SNVs related to drug resistance in each isolate.

99 **Methods**

100 Samples were collected as part of routine clinical practice with patient consent
101 and sent to the Clinical Microbiology Laboratory at the Hospital of the University of
102 Pennsylvania under the IRB protocol #829497. Respiratory samples were decontaminated
103 with NaOH and N-acetylcysteine and tissue specimens were pulverized in a tissue
104 grinder. Prepared specimens were inoculated on 7H11 selective and non-selective solid
105 media and a Mycobacterial Growth Indicator Tube (MGIT) broth. All cultures were
106 incubated at 35-37°C for 6 weeks. Positive cultures for *Mycobacteria* were identified at
107 the species level using *hsp65* gene sequencing. Susceptibility testing and MIC
108 determination was performed using the RAPMYCO microbroth dilution plate
109 (ThermoFisher) and susceptibility was determined using the CLSI M42 A2. Tigecycline
110 susceptibility breakpoints for the MIC have not been established for mycobacterium (10).
111 For our analysis, we based our tigecycline thresholds for resistance based on the Wallace
112 et al. (11). For antibiotic resistance gene investigation, we categorized susceptibility into
113 susceptible, intermediate, and resistant.

114 *Mycobacterium* samples had been previously frozen for routine clinical purposes
115 and were re-isolated on chocolate agar and propagated by growth in Middlebrook 7H9
116 media for 5 days. Multiple DNA purification methods were compared to identify one
117 producing high molecular weight DNA in good yield. Ultimately, DNA was purified
118 from each sample using a phenol-chloroform DNA extraction designed for high
119 molecular weight DNA (12). Long-read libraries were prepared using the Rapid
120 Barcoding Kit, version SQK-RBK004 (Oxford Nanopore, Oxford, UK) and sequenced on
121 the MinION using a R9.4.1 flow cell. Short-read libraries were prepared using the TruSeq

122 DNA Nano Library Prep Kit (Illumina, San Diego, CA), and sequenced on the HiSeq
123 2500 using 2x125 bp chemistry. *V. campbellii* was grown in Difco Marine broth 2216
124 culture media (BD) overnight and DNA was extracted using DNeasy Blood & Tissue
125 Kits (Qiagen). Short read libraries were prepared using the Nextera XT Library Prep Kit
126 (Illumina, San Diego, CA) and sequenced on the HiSeq 2500 using 2x125bp chemistry.
127 References genomes were all isolates that were whole genome sequenced and collected
128 from GenBank.

129 We used the Sunbeam pipeline to process the short reads and an in-house
130 pipeline, Nanoflow (<https://github.com/zhoac1/nanoflow>), to process the long reads and
131 perform the hybrid assembly (13). Short read processing included trimming adapters off
132 reads, filtering out low quality reads and removing low complexity reads (13). Long read
133 processing included base calling using Albacore, trimming adaptors, and filtering and
134 subsetting reads based on quality using Porechop (<https://github.com/rrwick/Porechop>)
135 and Filtlong (<https://github.com/rrwick/Filtlong>). Hybrid assembly was performed by two
136 methods: 1) using Canu, polishing with Nanopolish and correction by short reads with
137 Pilon or 2) using Unicycler, a program that uses the short read assembler Spades guided
138 by long reads as scaffolds, which is further polished by Pilon (14,15). CheckM and
139 alignment to reference genomes were used to check the quality of the draft genomes (16).

140 We used another in-house pipeline, CoreSNPs
141 (<https://github.com/chrgu/coreSNPs>) to investigate how related the isolates were to each
142 other. CoreSNPs uses Prokka for genome annotation, and Roary for investigating the
143 pangenome and creating a hierarchical cluster based on the presence and absence of
144 accessory genes (17,18). An in-house R script and shell script were used to extract the

145 core genes from the isolates to compare SNVs by hamming distance. The SNV analysis
146 used SamTools and SNP-sites (19,20). Approximately maximum-likelihood phylogenetic
147 trees for the core genes were generated by Fasttree 2 (21).

148 The threshold for identity was determined using a dataset of a single isolate of *V.*
149 *campbellii* sequenced 39 times (Illumina only) and examining the number of SNVs
150 between sequencing runs. The dataset was analyzed using the same in-house pipelines as
151 above. Roary defined core genes as genes present in 100% of the samples; 643 genes, or
152 ~12.5%, were not 100% conserved, likely due to gaps between contigs in the short read
153 only draft genomes.

154 We used Resistance Gene Identifier (RGI) on the output of Prokka to examine
155 resistance genes within the genome (22). We searched for both high identity and low
156 identity homologous hits to identify previously known and potentially novel resistance
157 genes, respectively. We also manually aligned known genes that can harbor resistance
158 mutations with Muscle to identify and compare mutations within the gene that
159 corresponded with drug susceptibility (23).

160 Nanoflow is available at www.github.com/zhaoc1/nanflow while all other
161 computer code used in this study is available at www.github.com/chrgu. *M. chelonae* and
162 *V. campbellii* assembled genomes available at GenBank under project PRJNA594977.

163

164 **Results**

165 *M. chelonae* was isolated from seven patients at the Hospital of the University of
166 Pennsylvania in 2017 (Table 1), including the two breast tissue cases. Ages ranged from

167 46 to 64. Sites of infection included skin (n=2), breast tissue (n=2), and respiratory tract
 168 (sampled as bronchial alveolar lavage (n=1) and sputum (n=2)).

169

170 **Table 1. Patient demographics and suspected pair of transmission.**

ID	SUSPECTED NOSOCOMIAL INFECTION PAIR*	AGE	SEX	SITE OF COLLECTION
MYCO1	X	45	Female	breast
MYCO2	X	47	Female	breast
MYCO3		61	Female	skin
MYCO4		64	Male	bronchiolar lavage
MYCO5		61	Male	sputum
MYCO6		61	Male	sputum
MYCO7		55	Male	leg skin

171

172

173 Drug susceptibility testing was performed on each isolate with 11 different
 174 antibiotics to determine the minimum inhibitory concentration (MIC) (Table 2). As
 175 expected, most of the isolates of *M. chelonae* were highly resistant to antibiotics, with
 176 only a few drugs such as clarithromycin, tigecycline, and tobramycin, effective against all
 177 the strains.

178

179 **Table 2. Antibiotic resistance profile of *M. chelonae* isolates with 11 antibiotics.**

ID	TMP*	LINE†	CIPRO§	IMI¶	MOXI#	CEFOX**	DOXY††	MINO§§	TIGE¶¶	TOBRA##	CLAR***
MYCO1	>8/152	32	4	16	8	>128	>16	4	0.5	4	0.5
	(R)	(R)	(R)	(I)	(R)	(R)	(R)	(I)	(S)	(I)	(S)
MYCO2	>8/152	32	>4	>64	8	>128	>16	>8	0.5	2	0.5
	(R)	(R)	(R)	(R)	(R)	(R)	(R)	(R)	(S)	(S)	(S)
MYCO3	>8/152	32	>4	16	8	128	>16	>8	0.5	2	0.5
	(R)	(R)	(R)	(I)	(R)	(R)	(R)	(R)	(S)	(S)	(S)

MYCO4	4/76 (R)	8 (S)	4 (R)	16 (I)	4 (R)	>128 (R)	>16 (R)	>8 (R)	0.5 (S)	<1 (S)	0.25 (S)
MYCO5	8/152 (R)	16 (I)	4 (R)	32 (R)	8 (R)	>128 (R)	>16 (R)	>8 (R)	0.25 (S)	2 (S)	0.5 (S)
MYCO6	>8/152 (R)	16 (I)	2 (I)	32 (R)	4 (R)	64 (I)	1 (S)	2 (I)	1 (S)	4 (I)	0.5 (S)
MYCO7	>8/152 (R)	>32 (R)	2 (I)	32 (R)	4 (R)	>128 (R)	>16 (R)	>8 (R)	0.5 (S)	2 (S)	2 (S)

180 Footnote: *TMP-SMX, †Linezolid, §Ciprofloxacin, ¶Imipenem, #Moxifloxacin,

181 **Cefoxitin, ††Doxycycline, §§Minocycline, ¶¶Tigecycline, ##Tobramycin,

182 ***Clarithromycin

183

184 The *M. chelonae* strains were isolated from seven patients at HUP during routine
 185 clinical treatment. Frozen stocks of the *M. chelonae* isolates were cultured and DNA was
 186 extracted. Extensive optimization was required to allow lysis of the tough *Mycobacterium*
 187 cell wall while preserving long DNA chains (see methods). DNA sequencing data was
 188 acquired using the Illumina HiSeq 2500 to generate short reads and the Oxford Nanopore
 189 MinION to generate long reads. Long-read assembly was carried out by Canu and
 190 polished by Nanopolish. The long-read assemblies were either 1) corrected with short-
 191 reads by Pilon or 2) used as scaffolds to guide short-read assembly by Unicycler, then
 192 further polished by Pilon in our hybrid assembly pipeline. Both assembly methods were
 193 used with each isolate and the best draft genome was chosen based on completeness (by
 194 checkM), number and length of contigs, and alignment to a reference genome. For one of
 195 our seven strains, Myco5, only short read assembly was carried out, due to difficulty in
 196 purifying high molecular weight DNA from this isolate.

197 In one case, two isolates were cultured from the same patient and analyzed
 198 separately (Myco3a/3b). In another case, a single genomic DNA preparation was

199 sequenced and assembled twice (Myco2a/b). Both pairs provide further empirical data on
200 the sources of error in library preparation and DNA sequencing.

201 The whole genome sequencing resulted in a range of contig numbers (n=1 to 76)
202 comprising the main chromosome. For those that were hybrid assembled, the range of
203 contigs was one to four. Three of the nine assemblies yielded complete circular contigs
204 for the main chromosome. The genomes ranged in size from 4.95 to 5.20 Mbp. No
205 clearly defined episomes were found, as judged by detection of extrachromosomal circles
206 (Table S1).

207 We assessed the phylogenetic relationships by comparing the number of single
208 nucleotide variants (SNVs) between core genes (genes found in every isolate), which
209 allowed us to interrogate potential transmission chains. We used all 43 whole genome
210 sequences of *M. chelonae* present in GenBank as reference to construct an approximately
211 maximum-likelihood phylogenetic tree. CheckM analysis were performed to ensure
212 completion and quality of the reference genomes prior to analysis. Analysis of our set of
213 *M. chelonae* genomes returned a total of 17,582 genes in the pan-genome, of which only
214 3,368 were considered core genes. The length of the total concatenated core genes per
215 genome was 3,296,947 bases. Within the core genes, the number of SNVs between
216 unique isolates ranged from 3,383 to 62,854. Our two samples from the same individual
217 (Myco3a and Myco3b) differed by 3 SNVs while our technical replicates (Myco2a and
218 Myco2b) differed by 2 SNVs. The potential transmission pair, Myco1 and Myco2a/b
219 differed by 16544/16542 SNVs in the core genes (SNVs are indicated for Myco2
220 replicates a and b, respectively). A maximum likelihood phylogenetic tree based on the
221 SNVs data is shown in Fig 1A. There was no obvious clustering of isolates with database

222 samples isolated from the same human body site, animal, or environmental source.
223 Likewise, the tree based on presence or absence of accessory genes (Fig 1B) also showed
224 the same.

225

226 **Fig 1. Relationship of *M. chelonae* genome sequences.**

227 A. An approximately maximum-likelihood phylogenetic tree showing relationships
228 among *M. chelonae* isolates based on SNVs in the core genes. Isolates from our study are
229 indicated with “Myco” and the isolate number. The sampling site and host of the isolate
230 is coded by color and shape, respectively, at branch tips. The scale at the bottom
231 represents the number of substitutions per sequence site based on length of the tree. B:
232 An approximately-maximum-likelihood tree showing relationship among *M. chelonae*
233 isolates based on presence or absence of accessory genes. C: SNVs per Mb core genome
234 between *M. chelonae* isolates. SNVs, calculated as hamming distance between the core
235 genes of all isolates divided by the total length of core genes. Myco2a/2b and Myco3a/3b
236 are technical and biological replicates, respectively.

237

238 To assess the likelihood of infection from a common point source, we next
239 empirically assessed the numbers of SNVs expected due to sequencing error in a larger
240 set of genomes. As a positive control in shotgun metagenomic studies, we repeatedly
241 sequenced a single bacterium, *V. campbellii*, a luciferase-encoding marine bacterium, that
242 was divergent from strains likely present in our samples. We recovered an average of
243 9,072,182 reads over 39 replicates, allowing generation of 39 full genome sequences.
244 Analysis of the *V. campbellii* genomes using Roary disclosed 4495 core genes in our

245 samples. Within the core genes, we found a range of SNVs from 0 to 74, with mean of 15
246 SNVs (Fig 2A). The total length for the concatenated core genes was 4,209,934 bases.
247 The two most divergent *V. campbellii* assemblies also had low sequence coverage
248 (Supplementary Table S2), indicating a rough upper bound on the number of SNV errors
249 associated with suboptimal sequence acquisition.

250

251 **Fig 2. Comparison of *Vibrio campbellii* genomes by SNVs per Mb core genome to**
252 **develop statistics for calling identity.**

253 A. The set of SNVs per Mb core genome, calculated by hamming distances divided by
254 length of core genome between the sequence sets for identical DNAs. B. Graph showing
255 the Hamming distances (x-axis) and the frequencies of distances between pairs (y-axis).
256 The distances between the technical and biological replicates are marked (Myco2a and
257 2b, and Myco 3a and 3b), as is the distance between the candidate transmission pair
258 (Myco1 and 2a).

259

260 This comparison takes advantage of Illumina sequence reads only, whereas our
261 *M. chelonae* isolates were sequenced using hybrid assembly of short and long reads. We
262 thus generated short read only assemblies for the *M. chelonae* isolates for a more direct
263 comparison to the *V. campbellii* dataset. Our short-read-only genomes contained slightly
264 fewer core genes (3,143 vs 3,368) compared to our hybrid assemblies. The short-read
265 genomes also had more SNVs per Mbp core genes. Both of our technical replicates
266 showed slightly higher SNV counts (3 and 64), but were lower than the maximum

267 number of SNVs for identical strains in our control *V. campbellii* dataset (the maximum
268 number of SNVs for any pair of isolates was 74).

269 The possible transmission pair, isolates Myco1 and Myco2a/b (Fig 3), differed by
270 16,542/16,544 SNVs in the core genes (Fig 2B), providing strong evidence that they are
271 different strains and not related by direct person-to-person transmission. This corresponds
272 to a difference of 5,237.58 SNVs per Mbp core genes. The smallest difference between
273 our isolated *M. chelonae* strains was 3426 SNVs in the core genes or 1038.18 SNVs per
274 Mbp core genes. Our technical replicates Myco3a and Myco3b differed by 3 SNVs (0.91
275 SNVs per Mbp core genes), and Myco2a and Myco2b differed by 2 SNVs (0.61 SNVs
276 per Mbp core genes) (Fig 1C). For comparison, the mean number of SNVs in pairwise
277 comparisons of *V. campbellii* control assemblies was 5.71 SNVs per Mbp core genes; the
278 maximum number was 17.62 SNVs per Mbp core genes (Fig 2B). The number of SNVs
279 in the candidate transmission pair thus far exceeds the number of SNVs that could be
280 generated by sequencing error per Mbp as seen from the *V. campbellii* controls and
281 exceeds the SNVs generated in our *M. chelonae* replicates (p-value < 0.001 by binomial
282 test). Thus, the data do not support transmission of a common strain from a single point
283 source, or a transmission event between the patients (Fig 2B).

284

285 **Fig 3. Comparison of genomes from the candidate transmission pair.**

286 Circos plots are shown of assemblies of Myco1 (left) and Myco2b (right). Each ring
287 represents, from inner to outer ring GC content; GC skew; RNA genes; genes unique to
288 the isolate, colored by COG function; and genes shared between the two isolates, colored
289 by COG function. Each genome was rotated to the origin of replication at the top.

290

291 The molecular determinants of antibiotic resistance in *M. chelonae* are not well
292 studied, so we sought to assess possible mechanisms disclosed in our sequence data.
293 Analysis using Resistance Gene Identifier (RGI) searching for high identity hits to
294 previously known genes related to resistance (22), yielded two partial hits to genes in all
295 the isolates, and a third in three of seven isolates. The two partial hits in all isolates were
296 *LRA-3* (100% identity) and *erm(38)* (80% identity); the third gene was *mtrA* (95.17%
297 identity). *LRA-3* is a gene coding for a beta-lactamase originally identified in soil samples
298 and could possibly contribute imipenem resistance (24). The gene, *erm(38)*, encodes for a
299 23S dimethyltransferase found in *Mycobacterium smegmatis* and can provide resistance
300 to macrolides and lincosomides (25). It has been shown to increase resistance to
301 Clarithromycin (26). *mtrA* is a gene from *Mycobacterium tuberculosis* whose expression
302 has been shown to influence cell morphology and drug resistance in *Mycobacterium*
303 *smegmatis* (27,28).

304 We also used RGI to identify genes with lower homology to known resistance
305 genes, providing possible starting points for follow up studies. We found a list of
306 candidate genes that may contribute to resistance and further narrowed down the list
307 using the susceptibility testing data by filtering out genes that were present in susceptible
308 populations and genes that were not present in intermediate or fully resistant populations.
309 Only 6 of the 11 drugs had low identity matches associated with their resistance pattern:
310 TMP-SMX (sulfonamide), ciprofloxacin (fluoroquinolone), moxifloxacin
311 (fluoroquinolone), imipenem (carbapenem), ceftiofur (cephalosporin), and Minocycline
312 (tetracycline). Genes are listed in Supplementary Table S3.

313 We further examined genes reported to be targets of mutations that may cause
314 resistance, such as mutations in 23S rRNA for linezolid resistance and *gyrA* for
315 fluoroquinolone resistance. There were no known or novel mutations present in the 23S
316 rRNA genes in our isolates that correlated with drug susceptibility or resistance. For
317 *gyrA*, we compared the two intermediate resistant isolates (Myco6 and Myco7) to five
318 resistant isolates. We found that there were no consistent mutations that resulted in
319 resistance, but Myco6 had two mutations (S710R and E773D) not present in the other
320 isolates and Myco7 had one mutation not present in the other isolates (T832A). These
321 amino acid changes might potentially modulate the resistance phenotype, though
322 functional confirmation is needed.

323

324 **Discussion**

325 Here we investigated the possibility of a nosocomial *M. chelonae* transmission at
326 the HUP in 2017 and found that there is no evidence to support a point source
327 outbreak. Our analysis found each isolate of *M. chelonae* was no more similar to each
328 other than to the strains collected from the NCBI database. This further supports that
329 these infections are likely acquired from the environment and not from a single point
330 source. Our analysis also supports the use of next generation sequencing to assess
331 possible nosocomial transmissions within the hospital environment.

332 To provide a control for sequencing error, we developed a dataset to help set a
333 threshold for use in calling identity between two isolates that takes account of error in
334 DNA sequence determination. We sequenced a strain of *V. campbellii* using the Illumina
335 method as a control 39 times independently. We found that the depth of sequencing

336 coverage correlated with the number of SNVs found in the genome assembly. The
337 number of SNVs ranged from 0 to 74 SNVs depending on which pair of sequencing runs
338 was compared, despite the same input DNA. There were several runs that though
339 following the same protocol, had higher numbers of SNVs on average when compared to
340 sequencing results of other runs, and these correlated with low sequence coverage
341 (Supplementary Table S2). Going forward, the data presented here provides a threshold
342 for comparing microbial genomes generally.

343 Our analysis also included two samples collected from the same individual and a
344 single isolate sequenced twice, again to help evaluate thresholds for calling identity
345 despite sequencing error. We found that our two samples from the same patient only
346 differed by 0.91 SNVs per Mbp core genes after our hybrid assembly; our single isolate
347 sequenced twice differed by 0.61 SNVs per Mbp core genes. These control *M. chelonae*
348 genomes show SNV numbers well within the range expected for identical sequences
349 based on our *V. campbellii* dataset. This indicates that the sequencing and hybrid
350 assembly pipeline works as expected to generate high quality genomes and allows
351 identification of identical organisms sequenced separately.

352 Our analysis also shed light on the host preferences of sequenced *M. chelonae*
353 strains. Some of our isolates were related to environmental samples such as water and sea
354 creatures, while others clustered with human isolates. Our data did not provide evidence
355 for a strongly human-associated clade.

356 Our investigation of the genetic basis of *M. chelonae* drug resistance was
357 inconclusive. Examination with Resistant Gene Identifier provided us a list with possible
358 resistance genes. While there were a few high identity resistance gene hits in our isolates,

359 the presence of these genes did not correspond with the drug susceptibility phenotypes.
360 For example, every isolate had an 80% identity hit to *erm(38)*, a gene found in *M.*
361 *smegmatis* to mediate resistance to macrolides, such as clarithromycin, but all of the
362 isolates were susceptible to clarithromycin. Thus, it is possible that the *erm(38)* homolog
363 in *M. chelonae* performs a different role. For *LRA-3*, a metallo-beta-lactamase gene, all
364 isolates were intermediately or fully resistant to the carbapenem tested. Since there are
365 two phenotypes in the presence of the gene, this suggests that it may play a role in
366 resistance, but other mechanisms may be involved as well. We also assessed low
367 homology hits to resistance genes and mutations in genes that are known to influence
368 drug susceptibility. For both, we have a narrow list of possible genes or mutations, but
369 given our low sample size, it is likely that most are false positives, and all require further
370 validation to confirm. Resistance in *M. chelonae* may in part be due to blocking entry of
371 antibiotics by the tough cell wall documented previously (29). Data presented here may
372 help guide future studies of mechanisms of resistance in *M. chelonae*.

373 In conclusion, we investigated a possible nosocomial outbreak of *M. chelonae* at
374 HUP. Our analysis concluded that no point source transmission occurred and that each
375 case of *M. chelonae* involved clearly distinct strains, likely acquired from the
376 environment. Our analysis also includes a dataset to help determine thresholds for
377 evaluating identity between different strains while controlling for sequencing error.
378 Finally, we queried potential antibiotic resistance mechanisms by genomic analysis,
379 providing candidate genes and mutations for potential follow up.

380

381 **Acknowledgements**

382 We are grateful to members of the Bushman laboratory for help and suggestions; and
383 Laurie Zimmerman for help with figures.

384

385 **Financial Disclosure Statement**

386 This work was supported by the Penn Center for AIDS Research P30 AI 045008; and the
387 PennCHOP Microbiome Program (<https://pennchopmicrobiome.chop.edu>).

388

389 **References**

- 390 1. Akram SM, Saleh D. Mycobacterium Chelonae. In Treasure Island (FL); 2019.
- 391 2. Donohue MJ, Wymer L. Increasing prevalence rate of nontuberculous
392 mycobacteria infections in five states, 2008-2013. Ann Am Thorac Soc. 2016;
- 393 3. Wang HX, Yue J, Han M, Yang JH, Gao RL, Jing LJ, et al. Nontuberculous
394 mycobacteria: Susceptibility pattern and prevalence rate in Shanghai from 2005 to
395 2008. Chin Med J (Engl). 2010;
- 396 4. Kennedy BS, Bedard B, Younge M, Tuttle D, Ammerman E, Ricci J, et al.
397 Outbreak of Mycobacterium chelonae Infection Associated with Tattoo Ink . N
398 Engl J Med. 2012;
- 399 5. Meyers H, Brown-Elliott BA, Moore D, Curry J, Truong C, Zhang Y, et al. An
400 Outbreak of Mycobacterium chelonae Infection Following Liposuction . Clin
401 Infect Dis. 2002;
- 402 6. Freitas D, Alvarenga L, Sampaio J, Mannis M, Sato E, Sousa L, et al. An outbreak
403 of Mycobacterium chelonae infection after LASIK. Ophthalmology. 2003;
- 404 7. Monego F, Duarte RS, Biondo AW. gyrA and gyrB Gene Mutation in

- 405 Ciprofloxacin-Resistant *Mycobacterium massiliense* Clinical Isolates from
406 Southern Brazil. *Microb Drug Resist* [Internet]. 2012;18(1):1–6. Available from:
407 <https://doi.org/10.1089/mdr.2011.0047>
- 408 8. Hillemann D, Rüsç-Gerdes S, Richter E. In vitro-selected linezolid-resistant
409 *Mycobacterium tuberculosis* mutants [4]. *Antimicrobial Agents and*
410 *Chemotherapy*. 2008.
- 411 9. Nessar R, Reyrat JM, Murray A, Gicquel B. Genetic analysis of new 16s rRNA
412 mutations conferring aminoglycoside resistance in *Mycobacterium abscessus*. *J*
413 *Antimicrob Chemother*. 2011;
- 414 10. Hatakeyama S, Ohama Y, Okazaki M, Nukui Y, Moriya K. Antimicrobial
415 susceptibility testing of rapidly growing mycobacteria isolated in Japan. *BMC*
416 *Infect Dis*. 2017;
- 417 11. Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the
418 in vitro activity of the glycylicline tigecycline (formerly GAR-936) with those of
419 tetracycline, minocycline, and doxycycline against isolates of nontuberculous
420 mycobacteria. *Antimicrob Agents Chemother*. 2002;
- 421 12. Van Soolingen D, Hermans PWM, De Haas PEW, Soll DR, Van Embden JDA.
422 Occurrence and stability of insertion sequences in *Mycobacterium tuberculosis*
423 complex strains: Evaluation of an insertion sequence-dependent DNA
424 polymorphism as a tool in the epidemiology of tuberculosis. *J Clin Microbiol*.
425 1991;
- 426 13. Clarke EL, Taylor LJ, Zhao C, Connell A, Lee JJ, Fett B, et al. Sunbeam: An
427 extensible pipeline for analyzing metagenomic sequencing experiments.

- 428 Microbiome. 2019;
- 429 14. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome
430 assemblies from short and long sequencing reads. PLoS Comput Biol.
431 2017;13(6):1–22.
- 432 15. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al.
433 SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell
434 Sequencing. J Comput Biol. 2012;
- 435 16. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM:
436 Assessing the quality of microbial genomes recovered from isolates, single cells,
437 and metagenomes. Genome Res. 2015;
- 438 17. Seemann T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics. 2014;
- 439 18. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary:
440 Rapid large-scale prokaryote pan genome analysis. Bioinformatics. 2015;
- 441 19. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
442 Alignment/Map format and SAMtools. Bioinformatics. 2009;
- 443 20. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites:
444 rapid efficient extraction of SNPs from multi-FASTA alignments. Microb
445 Genomics. 2016;
- 446 21. Price MN, Dehal PS, Arkin AP. FastTree 2 - Approximately maximum-likelihood
447 trees for large alignments. PLoS One. 2010;
- 448 22. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, et al. CARD
449 2017: Expansion and model-centric curation of the comprehensive antibiotic
450 resistance database. Nucleic Acids Res. 2017;

- 451 23. Edgar RC. MUSCLE: Multiple sequence alignment with high accuracy and high
452 throughput. *Nucleic Acids Res.* 2004;
- 453 24. Allen HK, Moe LA, Rodbumer J, Gaarder A, Handelsman J. Functional
454 metagenomics reveals diverse B-lactamases in a remote Alaskan soil. *ISME J.*
455 2009;
- 456 25. Madsen CT, Jakobsen L, Douthwaite S. *Mycobacterium smegmatis* Erm(38) is a
457 reluctant dimethyltransferase. *Antimicrob Agents Chemother.* 2005;
- 458 26. Nash KA. Intrinsic macrolide resistance in *Mycobacterium smegmatis* is conferred
459 by a novel erm gene, erm(38). *Antimicrob Agents Chemother.* 2003;
- 460 27. Rouquette C, Harmon JB, Shafer WM. Induction of the mtrCDE-encoded efflux
461 pump system of *Neisseria gonorrhoeae* requires MtrA, an AraC-like protein. *Mol*
462 *Microbiol.* 1999;
- 463 28. Li Y, Zeng J, Zhang H, He ZG. The characterization of conserved binding motifs
464 and potential target genes for *M. tuberculosis* MtrAB reveals a link between the
465 two-component system and the drug resistance of *M. smegmatis*. *BMC Microbiol.*
466 2010;
- 467 29. Jarlier V, Nikaido H. Mycobacterial cell wall: Structure and role in natural
468 resistance to antibiotics. *FEMS Microbiology Letters.* 1994.

469

470

471 **Supplementary Material**

472 **S1 Table. Genome sequences analyzed in this study.**


473 **S2 Table. *Vibrio campbellii* assembly information.**

474 **S3 Table. List of potential *Mycobacterium chelonae* resistance genes by drug type**

Figure 1

A

bioRxiv preprint doi: <https://doi.org/10.1101/2020.07.10.196873>; this version posted July 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



Legend

Sample origin

- environment
- human
- ▲ python
- ◆ sea creature

Specific source

- aquarium biofilm
- arm
- body
- head
- leg
- organ
- respiratory
- skin
- soft tissue
- water
- NA

Figure 1a

Figure 1

B




Figure 1b

Figure 1


C SNVs per Mb core genes for *Mycobacterium chelonae* isolates

Figure 1c

Figure 2

SNVs per Mb core genes for Vibrio core genomes

A




Figure 2a

Figure 2

B





Figure 2b

Figure 3



COG function




Figure 3